$3.530
-0.293 (-8.31%)At close
- High
- 3.825
- Open
- 3.800
- VWAP
- 3.63
- Vol
- 54.16K
- Mkt Cap
- —
- Low
- 3.530
- Amount
- 196.50K
- EV/EBITDA, TTM
- -1.20
BioStem Technologies, Inc. is focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The Company's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. It also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines.
AI analysis of BioStem Technologies, Inc. (BSEM)
holdBiostem Technologies, Inc. is currently a hold. The stock price is at $3.53, with a forward P/E ratio of 17.42, indicating potential for growth if the company can maintain its revenue trajectory. However, the stock has experienced a significant year-to-date decline of 19.77%, and recent earnings showed a reported EPS of -0.52, which is a risk factor.
Valuation Metrics
BSEM FAQ — answered by Alphio AI
BioStem Technologies, Inc. is focused on harnessing the natural properties of perinatal tissue in the development, manufacture and commercialization of allografts and regenerative therapies. Leveraging its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The Company's products include VENDAJE, VENDAJE AC, VENDAJE OPTIC and AMERICAN AMNION. VENDAJE is a structural tissue allograft composed of the amnion layer of the placental membrane. VENDAJE is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE AC is a thicker structural tissue allograft composed of the amnion and chorion layer of the placental membrane. VENDAJE AC is intended for homologous use as a protective covering for soft tissue wounds. VENDAJE OPTIC is a structural tissue allograft composed of the amnion layer of the placental membrane. It also owns BioTissue's surgical and wound care business, including the Neox and Clarix product lines. It operates in the Healthcare sector.
Biostem Technologies, Inc. is currently a hold. The stock price is at $3.53, with a forward P/E ratio of 17.42, indicating potential for growth if the company can maintain its revenue trajectory. However, the stock has experienced a significant year-to-date decline of 19.77%, and recent earnings showed a reported EPS of -0.52, which is a risk factor.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.